37 results about "Erythroblast" patented technology

Mithramycin derivatives and their pharmaceutically acceptable salts are disclosed. The mithramycin derivatives can be used in the treatment of Ewing sarcoma or other cancer or neuro-disease associated with an aberrant erythroblast transformation-specific transcription factor.

We describe a new two-step culture method for mass production in vitro of erythroid cells from either CD34+ (105 cells / mL) or light-density (106 cells / mL) cells purified from the blood of normal donors and thalassemic patients. The method includes (i) culture of the cells in the presence of dexamethasone and estradiol (10−6 M each) and (ii) the growth factors SCF (50 ng / mL), IL-3 (1 ng / mL), and EPO (1 U / mL). In their proliferative phase, these cultures generated about 1-2×107 erythroblasts for each milliliter of blood collected from normal donors or thalassemic patients. They were composed mostly (90%) of CD45low / glycophorin (GPA)neg / CD71low cells at day 7, 50-60% of which became CD45neg / GPA+ / CD71high by days 15-20. However, when cells from days 7 to 12 of the proliferative phase were transferred in differentiation medium containing EPO and insulin, they progressed to mature erythroblasts (>90% benzidinepos and CD45neg / GPA+ / CD71medium) in 4 days. Because of the high number of erythroid cells that are generated from modest volumes of blood, this method will prove useful in donor-specific studies of erythroid differentiation.

Described herein is a method of differentiation of pluripotent stem cells into hematopoietic precursor cells, hematopoietic progenitor cells, erythroblast cells, and enucleated erythroblast cells, wherein the method is carried out under suspension agitation, and a GSK-3-inhibitor or a Wnt pathway activator is added during a stage of mesoderm induction. In the preferred embodiment, the pluripotentstem cells are expanded in agitated microcarrier culture and the GSK-3-inhibitior is CHIR99021. Also disclosed herein are cell culture media for use in the methods disclosed herein, as well as kits for performing the same.

The enumeration and analysis of residual white blood cells in a sample of leukocyte-reduced blood products is conducted by forming a suspension of the leukocyte-reduced blood products with a sufficient amount of a lysing reagent. The lysing reagent comprises a buffer with a low molar concentration, and a non-ionic surfactant. The suspension of leukocyte-reduced blood products and the lysing reagent is incubated for a sufficient time at a temperature sufficient to selectively lyse the platelets and red blood cells without damaging the white blood cells. The white blood cells of the lysed blood products are then contacted with a suitable dye to stain the white blood cells and the number of stained white blood cells is measured. The lysing reagent is free of harsh organic solvents which can damage the plastic components of automated clinical analyzers.

The present invention provides therapeutic mammalian cells which synthesize and express SS hemoglobin and a tumoricidal transgene. They are produced by transduction of SS erythroid progenitors / erythroblasts using viral vectors comprising a tumoricidal transgene operatively linked to the coding region of SS β-globin promoter / enhancer. Such transduced SS erythroid cells differentiate into mature SSRBCs that exhibit sustained synthesis and expression of SS hemoglobin, a tumoricidal protein(s). Both mature and progenitor SS-cells carrying tumoricidal transgene(s) are capable of selectively localizing in tumor microenvironment, occluding tumor microvessels and inducing a tumoricidal response.

There is provided a method for identifying at least one foetal erythroblast the method comprising: (a) detecting the expression of at least one foetal erythroblast specific marker selected from the group consisting of neutral amino acid transporter B (SLC1A5), solute carrier family 3 (activators of dibasic and neutral amino acid transport) member 2 isoform A (SLC3A2), Splice Isoform A of Chloride channel protein 6, Transferrin receptor protein 1, Splice Isoform 3 of Protein GPR107 precursor, Olfactory receptor 11H4, Splice Isoform 1 of Protein C9orf5, Cleft lip and palate transmembrane protein 1, BCG induced integral membrane protein BIGM103, Antibacterial protein FALL-39 precursor, CAAX prenyl protease 1 homolog, Splice Isoform 2 of Synaptophysin-like protein, Vitamin K epoxide reductase complex subunit 1-like protein 1, Splice Isoform 1 of Protein C20orf22 (ABHD12), Hypothetical protein DKFZp564K247 (Hypoxia induced gene 1 protein) (IPI Accession No. IPI00295621), Hypothetical protein DK-FZp586C1924 (IPI Accession No. IPI00031064), ALEX3 protein variant, Hypothetical protein MGC14288 (IPI Accession No. IPI00176708), protein with IPI Accession No. IPI00639803 and protein with IPI Accession No. IPI00646289, wherein detection of the marker indicates the presence of the foetal erythroblast.

Techniques are provided for detecting hematological disorders using cell-free DNA in a blood sample, e.g., using plasma or serum. For example, an assay can target one or more differentially-methylated regions specific to a particular hematological cell lineage (e.g., erythroblasts). A methylation level can be quantified from the assay to determine an amount of methylated or unmethylated DNA fragments in a cell-free mixture of the blood sample. The methylation level can be compared to one or more cutoff values, e.g., that correspond to a normal range for the particular hematological cell lineage as part of determining a level of a hematological disorder.

The invention discloses a high-throughput rapid classification and analysis method for blood cells suitable for common fish such as crucian carp and carp. Aiming at the problem that nucleated red blood cells that cannot be removed interfere with white blood cell classification and counting in terms of quantity and shape, an automated measurement and analysis strategy combining fluorescent dyes and multi-channel images is used to separate the interference The red blood cell samples are separated from the white blood cells, and the range of different white blood cell groups that undertake important immune functions such as lymphocytes, monocytes, and granulocytes is divided, and automatic analysis is completed. The difficulty of effectively removing nucleated red blood cells has long plagued the automatic analysis of blood images of many types of animals. This invention combines fluorescent dyes with image analysis, and uses the high-throughput and high-sensitivity measurement modules of the multi-dimensional panoramic analyzer to accurately identify red blood cell groups. Eliminating its interference provides important technical support for focused analysis of leukocyte groups and has broad application prospects.

The invention discloses a method for separating and identifying nucleated erythrocytes in blood, which comprises the following steps: (1) preparing reagents; (2) preparing anti-degumming glass slides; Operation method to obtain nucleated red blood cells in the blood. The method for separating and identifying nucleated red blood cells in blood of the present invention can effectively identify nucleated red blood cells, all 40 samples can detect nucleated red blood cells, the detection rate is 100%, and 2×106 to 6×106 nucleated red blood cells were found in each case ml. The present invention is easy to identify nucleated red blood cells after benzidine staining, and can quickly obtain single nucleated red blood cells by skilled micromanipulation, laying a good preliminary foundation for applying single nucleated red blood cells to gene analysis.

The present invention provides a human cell population that can self-renew extensively and yet retain the capacity to differentiate into red blood cells (RBCs). These cells are referred to as extensively self-renewing erythroblasts (ESREs). The cells of the invention serve among other things as a renewable source of transfusable RBCs.